Merck & Co. (MRK) said Thursday that it has voluntarily withdrawn its biologics license application with Daiichi Sankyo seeking approval for patritumab deruxtecan in the US.
The application was based on the HERTHENA-Lung01 phase 2 trial for the treatment of certain adult patients with non-small cell lung cancer.
The company said it decided to withdraw the application because the topline overall survival results from the confirmatory HERTHENA-Lung02 phase 3 trial did not meet statistical significance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.